Search Results - "Boshuizen, Julia"

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch by Kong, Xiangjun, Kuilman, Thomas, Shahrabi, Aida, Boshuizen, Julia, Kemper, Kristel, Song, Ji-Ying, Niessen, Hans W. M., Rozeman, Elisa A., Geukes Foppen, Marnix H., Blank, Christian U., Peeper, Daniel S.

“…The identification of an ERK2–JUNB–FRA1 signalling pathway that drives addiction to therapeutic drugs in cancer cells, and an ERK2-dependent phenotype switch…”
Get full text

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance by Boshuizen, Julia, Vredevoogd, David W., Krijgsman, Oscar, Ligtenberg, Maarten A., Blankenstein, Stephanie, de Bruijn, Beaunelle, Frederick, Dennie T., Kenski, Juliana C. N., Parren, Mara, Brüggemann, Marieke, Madu, Max F., Rozeman, Elisa A., Song, Ji-Ying, Horlings, Hugo M., Blank, Christian U., van Akkooi, Alexander C. J., Flaherty, Keith T., Boland, Genevieve M., Peeper, Daniel S.

“…Melanomas can switch to a dedifferentiated cell state upon exposure to cytotoxic T cells. However, it is unclear whether such tumor cells pre-exist in patients…”
Get full text

Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling by Apriamashvili, Georgi, Vredevoogd, David W., Krijgsman, Oscar, Bleijerveld, Onno B., Ligtenberg, Maarten A., de Bruijn, Beaunelle, Boshuizen, Julia, Traets, Joleen J. H., D’Empaire Altimari, Daniela, van Vliet, Alex, Lin, Chun-Pu, Visser, Nils L., Londino, James D., Sanchez-Hodge, Rebekah, Oswalt, Leah E., Altinok, Selin, Schisler, Jonathan C., Altelaar, Maarten, Peeper, Daniel S.

“…The cytokine IFNγ differentially impacts on tumors upon immune checkpoint blockade (ICB). Despite our understanding of downstream signaling events, less is…”
Get full text

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance by Boshuizen, Julia, Vredevoogd, David W., Krijgsman, Oscar, Ligtenberg, Maarten A., Blankenstein, Stephanie, de Bruijn, Beaunelle, Frederick, Dennie T., Kenski, Juliana C. N., Parren, Mara, Brüggemann, Marieke, Madu, Max F., Rozeman, Elisa A., Song, Ji-Ying, Horlings, Hugo M., Blank, Christian U., van Akkooi, Alexander C. J., Flaherty, Keith T., Boland, Genevieve M., Peeper, Daniel S.

Get full text

Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase by van Veen, J Edward, Scherzer, Michael, Boshuizen, Julia, Chu, Mollee, Liu, Annie, Landman, Allison, Green, Shon, Trejo, Christy, McMahon, Martin

“…Human lung adenocarcinoma exhibits a propensity for de-differentiation, complicating diagnosis and treatment, and predicting poorer patient survival. In…”
Get full text

TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction by Vredevoogd, David W, Apriamashvili, Georgi, Levy, Pierre L, Sinha, Sanju, Huinen, Zowi R, Visser, Nils L, de Bruijn, Beaunelle, Boshuizen, Julia, van Hal-van Veen, Susan E, Ligtenberg, Maarten A, Bleijerveld, Onno B, Lin, Chun-Pu, Díaz-Gómez, Judit, Sánchez, Santiago Duro, Markovits, Ettai, Simon Nieto, Juan, van Vliet, Alex, Krijgsman, Oscar, Markel, Gal, Besser, Michal J, Altelaar, Maarten, Ruppin, Eytan, Peeper, Daniel S

“…Background Blockade of the programmed cell death protein 1 (PD-1) immune checkpoint (ICB) is revolutionizing cancer therapy, but little is known about the…”
Get full text

Rational Cancer Treatment Combinations: An Urgent Clinical Need by Boshuizen, Julia, Peeper, Daniel S.

“…We are witnessing several revolutionary technological advances in cancer. These innovations have not only contributed to a growing understanding of the tumor…”
Get full text

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold by Vredevoogd, David W., Kuilman, Thomas, Ligtenberg, Maarten A., Boshuizen, Julia, Stecker, Kelly E., de Bruijn, Beaunelle, Krijgsman, Oscar, Huang, Xinyao, Kenski, Juliana C.N., Lacroix, Ruben, Mezzadra, Riccardo, Gomez-Eerland, Raquel, Yildiz, Mete, Dagidir, Ilknur, Apriamashvili, Georgi, Zandhuis, Nordin, van der Noort, Vincent, Visser, Nils L., Blank, Christian U., Altelaar, Maarten, Schumacher, Ton N., Peeper, Daniel S.

“…New opportunities are needed to increase immune checkpoint blockade (ICB) benefit. Whereas the interferon (IFN)γ pathway harbors both ICB resistance factors…”
Get full text

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors by Boshuizen, Julia, Koopman, Louise A, Krijgsman, Oscar, Shahrabi, Aida, van den Heuvel, Elke Gresnigt–, Ligtenberg, Maarten A, Vredevoogd, David W, Kemper, Kristel, Kuilman, Thomas, Song, Ji-Ying, Pencheva, Nora, Mortensen, Jens Thing, Foppen, Marnix Geukes, Rozeman, Elisa A, Blank, Christian U, Janmaat, Maarten L, Satijn, David, Breij, Esther C W, Peeper, Daniel S, Parren, Paul W H I

“…Expression of AXL earmarks melanoma cells resistant to BRAF and MEK inhibitors that either pre-exist in treatment-naive tumors or emerge in response to…”
Get full text

Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade by Boshuizen, Julia, Pencheva, Nora, Krijgsman, Oscar, Altimari, Daniela D'Empaire, Castro, Patricia Garrido, de Bruijn, Beaunelle, Ligtenberg, Maarten A, Gresnigt-Van den Heuvel, Elke, Vredevoogd, David W, Song, Ji-Ying, Visser, Nils, Apriamashvili, Georgi, Janmaat, Maarten L, Plantinga, Theo S, Franken, Patrick, Houtkamp, Mischa, Lingnau, Andreas, Jure-Kunkel, Maria, Peeper, Daniel S

“…Although immune checkpoint blockade (ICB) has shown remarkable clinical benefit in a subset of patients with melanoma and lung cancer, most patients experience…”
Get full text

Abstract 4591: Specific elimination of invasive and multidrug-resistant cancer cells by an antibody-drug conjugate targeting AXL by Boshuizen, Julia, Koopman, Louise A., Breij, Esther C., Satijn, David, Peeper, Daniel, Parren, Paul W.

“…Abstract Upon therapeutic pressure, cancers commonly select for drug-resistant, invasive subpopulations with elevated expression of the receptor tyrosine…”
Get full text

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness by Lin, Chun-Pu, Levy, Pierre L, Alflen, Astrid, Apriamashvili, Georgi, Ligtenberg, Maarten A, Vredevoogd, David W, Bleijerveld, Onno B, Alkan, Ferhat, Malka, Yuval, Hoekman, Liesbeth, Markovits, Ettai, George, Austin, Traets, Joleen J H, Krijgsman, Oscar, van Vliet, Alex, Poźniak, Joanna, Pulido-Vicuña, Carlos Ariel, de Bruijn, Beaunelle, van Hal-van Veen, Susan E, Boshuizen, Julia, van der Helm, Pim W, Díaz-Gómez, Judit, Warda, Hamdy, Behrens, Leonie M, Mardesic, Paula, Dehni, Bilal, Visser, Nils L, Marine, Jean-Christophe, Markel, Gal, Faller, William J, Altelaar, Maarten, Agami, Reuven, Besser, Michal J, Peeper, Daniel S

“…Genes limiting T cell antitumor activity may serve as therapeutic targets. It has not been systematically studied whether there are regulators that uniquely or…”
Get more information

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold by Vredevoogd, David W., Kuilman, Thomas, Ligtenberg, Maarten A., Boshuizen, Julia, Stecker, Kelly E., de Bruijn, Beaunelle, Krijgsman, Oscar, Huang, Xinyao, Kenski, Juliana C.N., Lacroix, Ruben, Mezzadra, Riccardo, Gomez-Eerland, Raquel, Yildiz, Mete, Dagidir, Ilknur, Apriamashvili, Georgi, Zandhuis, Nordin, van der Noort, Vincent, Visser, Nils L., Blank, Christian U., Altelaar, Maarten, Schumacher, Ton N., Peeper, Daniel S.

Get full text

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4 by Krijgsman, Oscar, Kemper, Kristel, Boshuizen, Julia, Vredevoogd, David W, Rozeman, Elisa A, Ibanez Molero, Sofia, de Bruijn, Beaunelle, Cornelissen-Steijger, Paulien, Shahrabi, Aida, Del Castillo Velasco-Herrera, Martin, Song, Ji-Ying, Ligtenberg, Maarten A, Kluin, Roelof J C, Kuilman, Thomas, Ross-Macdonald, Petra, Haanen, John B A G, Adams, David J, Blank, Christian U, Peeper, Daniel S

“…Combining anti-PD-1 + anti-CTLA-4 immune-checkpoint blockade (ICB) shows improved patient benefit, but it is associated with severe immune-related adverse…”
Get full text

Mutationally-activated PI3'-kinase-α promotes de-differentiation of lung tumors initiated by the BRAF V600E oncoprotein kinase by van Veen, J Edward, Scherzer, Michael, Boshuizen, Julia, Chu, Mollee, Liu, Annie, Landman, Allison, Green, Shon, Trejo, Christy, McMahon, Martin

“…Human lung adenocarcinoma exhibits a propensity for de-differentiation, complicating diagnosis and treatment, and predicting poorer patient survival. In…”
Get full text

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency by YUQIAO SHEN, REHMAN, Farah L, YING FENG, BOSHUIZEN, Julia, BAJRAMI, Ilirjana, ELLIOTT, Richard, BING WANG, LORD, Christopher J, POST, Leonard E, ASHWORTH, Alan

“…PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair. Here, we describe BMN 673, a novel, highly potent PARP1/2…”
Get full text